Last reviewed · How we verify
Pteramina (AMINOPTERIN)
Pteramina works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division.
Pteramina (Aminopterine) is a small molecule drug that targets dihydrofolate reductase, an enzyme involved in DNA synthesis. It is classified as an aminopterin and has been used to treat leukemia and other diseases. The commercial status of Pteramina is unclear, and it may be patented or off-patent. As a result, it may be available from generic manufacturers or not. Further information on its FDA approval status, half-life, and bioavailability is not available.
At a glance
| Generic name | AMINOPTERIN |
|---|---|
| Drug class | aminopterin |
| Target | Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Think of it like a roadblock for cells to make new DNA. When cells try to divide and grow, they need to make new DNA, but Pteramina blocks the enzyme that helps make that DNA. This can be helpful in treating diseases like leukemia, where cells are growing too quickly.
Approved indications
- Leukemia, disease
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2,PHASE3)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2,PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pteramina CI brief — competitive landscape report
- Pteramina updates RSS · CI watch RSS